MedTrace Logo

An Open Label Trial Evaluating the Efficacy of Lacticaseibacillus Paracasei PS23 on Cognition

NCT07168824 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-12-05

No results posted yet for this study

Summary

This open label study aims to evaluate whether the consumption of probiotics can improve symptoms and overall quality of life in individuals experiencing cognitive decline symptoms, as well as to evaluate the effects of probiotics on blood-related biomarkers.

Conditions

  • Subjective Cognitive Decline (SCD)

Interventions

DIETARY_SUPPLEMENT

Lacticaseibacillus paracasei

one capsule daily for 12 weeks

Sponsors & Collaborators

  • Bened Biomedical Co., Ltd.

    collaborator INDUSTRY

  • Chi-Chang Huang

    lead OTHER

Principal Investigators

  • Chi-Chang Huang, PhD · National Taiwan Sport University

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-17
Primary Completion
2026-08-18
Completion
2026-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07168824 on ClinicalTrials.gov